ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Comfortably above the $2 NASDAQ delist line

<< Previous

Bullboard Posts

Next >>

Comment by garygpon Jan 18, 2024 2:33pm

152 Views

Post# 35834265

RE:RE:RE:RE:Comfortably above the $2 NASDAQ delist line

Once this took off a week or two ago, the group that naked shorted this last July got nervous and thought it best to cover that short. That would be prudent imo as there was a ton of stock shorted.

I also think the stock got ahead of itself with thoughts that there was "some kind" of news coming out of the recent AAIC in San Francisco that didn't materialize, at least not yet. Early 1a news may not be too far off which could give us a bit of a boost.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages